1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
- 2015
-
Mark
Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study
(
- Contribution to journal › Article
- 2012
-
Mark
Homozygous deletions of CDKN2A are present in all dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukaemias and may be important for leukaemic transformation
(
- Contribution to journal › Letter
- 2010
-
Mark
Late complications of childhood acute lymphoblastic leukaemia (ALL), with special reference to hormone secretion, cardiovascular risk and bone health
2010)(
- Thesis › Doctoral thesis (compilation)
- 2009
-
Mark
Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia
(
- Contribution to journal › Article
- 2008
-
Mark
Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival
(
- Contribution to journal › Article
- 2007
-
Mark
Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
(
- Contribution to journal › Article
-
Mark
Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia
(
- Contribution to journal › Article
- 2005
-
Mark
Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience
(
- Contribution to journal › Article
- 2003
-
Mark
Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents
(
- Contribution to journal › Article